<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389840</url>
  </required_header>
  <id_info>
    <org_study_id>CMX-DS-004</org_study_id>
    <nct_id>NCT04389840</nct_id>
  </id_info>
  <brief_title>Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure</brief_title>
  <official_title>A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and
      efficacy of DSTAT in patients with Acute Lung Injury (ALI) due to COVID-19. This study is
      designed to determine if DSTAT can accelerate recovery and prevent progression to mechanical
      ventilation in patients severely affected by COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 1:1 randomized, double-blind, placebo-controlled, Phase 2/3 trial to evaluate
      the safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of
      respiratory failure. Eligible subjects will be those with confirmed COVID-19 who require
      hospitalization and supplemental oxygen therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who are alive and free of invasive mechanical ventilation</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Alive and free of invasive mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Time to all-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">524</enrollment>
  <condition>COVID-19</condition>
  <condition>Acute Lung Injury</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Dociparstat sodium (DSTAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dociparstat 4 mg/kg IV bolus on Day 1, followed by Dociparstat by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dociparastat sodium</intervention_name>
    <description>Dociparstat is a glycosaminoglycan derived from porcine heparin.</description>
    <arm_group_label>Dociparstat sodium (DSTAT)</arm_group_label>
    <other_name>DSTAT</other_name>
    <other_name>CX-01</other_name>
    <other_name>2-0,3-0 desulfated heparin</other_name>
    <other_name>ODSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
    <other_name>Sodium chloride 0.9%</other_name>
    <other_name>0.9% Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized for laboratory-documented COVID-19 disease (e.g., positive for SARS-CoV-2
             via nasopharyngeal swab RT-PCR [or other commercial or public health assay]).

          2. Age ≥18 years and ≤85 years.

          3. Resting oxygen saturation (SaO2) of &lt;94% while breathing ambient air.

          4. Score of 3 or 4 on the NIAID ordinal scale (requires supplemental oxygen or
             noninvasive ventilation).

          5. Provide informed consent to participate in the study (by participant or
             legally-acceptable representative).

        Exclusion Criteria:

          1. Currently receiving invasive mechanical ventilation (e.g., via an endotracheal tube)
             (score of 2 on NIAID ordinal scale).

          2. Active or uncontrolled bleeding at the time of randomization; a bleeding disorder,
             either inherited or caused by disease; history of known arterial-venous malformation,
             intracranial hemorrhage, or suspected or known cerebral aneurysm; or clinically
             significant (in the judgment of the investigator) gastrointestinal bleeding within the
             3 weeks prior to randomization.

          3. Receiving any other investigational (non-approved) therapy for the treatment of
             COVID-19 or participating in the treatment period of any other therapeutic invention
             clinical study.

          4. Receiving systemic corticosteroids for a chronic condition.

          5. Receiving chronic anticoagulation with warfarin or direct oral anticoagulants (e.g.,
             rivaroxaban, dabigatran, apixaban, edoxaban).

          6. Receiving or anticipated to require other systemic anticoagulation dosing at a
             therapeutic intensity. Prophylaxis of VTE using SC unfractionated heparin or
             enoxaparin is permitted with appropriate monitoring of coagulation status and within
             guidelines provided in the protocol.

          7. Receiving antiplatelet therapy, alone or in combination, including aspirin and other
             antiplatelet agents (e.g., clopidogrel, ticagrelor, and prasugrel), unless able to
             discontinue these agents at the time of randomization and to remain off these agents
             throughout the duration of the study intervention infusion period.

          8. Treatment with systemic (nonsteroid) immunomodulators or immunosuppressant
             medications, including but not limited to TNF inhibitors, anti-interleukin-1 agents,
             and Janus kinase (JAK) inhibitors within 5 half-lives or 30 days (whichever is longer)
             prior to randomization.

          9. Severe chronic liver disease.

         10. Severe renal impairment.

         11. QTc &gt;500 msec (or &gt;530-550 msec in patients with QRS greater than &gt;120 msec).

         12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;5x upper limit of
             normal (ULN).

         13. Activated partial thromboplastin time (aPTT) &gt;42 seconds.

         14. Thrombocytopenia with a platelet count &lt;80,000/mm3.

         15. Evidence of clinical improvement in COVID-19 status including, but not limited to, a
             sustained reduction in oxygen requirements over the previous 48 hours, or extubated
             and/or no longer requiring mechanical ventilation following intubation for COVID-19.

         16. Any other condition, including abnormal laboratory values, that, in the judgment of
             the investigator, could put the participant at increased risk, or would interfere with
             the conduct or planned analysis of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Morrison, MD</last_name>
    <phone>919-313-2977</phone>
    <email>mmorrison@chimerix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth MacLeod</last_name>
    <phone>919-287-6029</phone>
    <phone_ext>211</phone_ext>
    <email>emacleod@chimerix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tejaswini Kulkarni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Pulmonary Research Institute/Wellington Regional Medical Center</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Warshoff, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Vincent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Lasky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyotsna Fuloria, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Friedman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Health Harris Methodist Hospital Fort Worth</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl McDonald, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Clinical Trials</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony J. Quaranta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ascension St. Francis Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Treisman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ascension All Saints Hospital</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Choi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ALI</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

